Differences between men and women in the use of preventive medications following a major cardiovascular event: Australian prospective cohort study

Abstract Most cardiovascular disease (CVD) events can be prevented with appropriate risk management. Existing evidence suggests women are less likely than men to receive guideline-recommended medications, however data on sex-differences in preventive medication use following a CVD event are lacking. Relative risks (RRs) comparing use of blood pressure- and lipid-lowering medications in men and women at 3-, 6-, 9- and 12-months following hospitalisation for myocardial infarction (MI) or stroke from 2012 to 2017 were quantified using linked data from 8,278 participants enrolled in the Australian 45 and Up Study. Overall, 51% of women and 58% of men were using both blood-pressure- and lipid-lowering medications three months after a MI or stroke event, decreasing to 48% and 53%, respectively, at 12 months after an event. Adjusting for potential confounders, women were 9% less likely than men (RR=0.91 [95% CI: 0.87, 0.95]) to be using both medications and 19% more likely (RR=1.19 [95% CI: 1.07, 1.32]; 16 vs. 13%) to use neither medication three months after a MI or stroke event. At the 12-month mark, women were 8% less likely (RR=0.92 [95% CI: 0.88, 0.97]) to be using both medications and 14% more likely (RR=1.14 [95% CI: 1.03, 1.26]) to use neither medication. Women were consistently less likely to use both preventive medications and more likely to use neither medication at each follow-up time point. Overall, there were major shortfalls in basic preventive medication use post-CVD event and sex disparities are likely to further jeopardise efforts to reduce CVD events in the community.